Unified Patent Court (UPC) analytics are now available. Check here

IP Verse

Amgen Europe patent opposition analysis

Get Patent Opposition Report for Amgen Europe

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Latest oppositions filed by Amgen Europe

Explore patent oppositions filed by Amgen Europe against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent NumberTitleApplicantOpposition Date
EP3345607Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or AgonistOSSIFI MABJul 26, 2023
EP3145487Liquid Pharmaceutical CompositionARES TRADINGDec 20, 2018

Latest patents of Amgen Europe opposed by its competitors

Explore Amgen Europe's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP2651400Jan 18, 2023Controlled Release Oral Dosage Forms Of Poorly Soluble Drugs And Uses Thereof1
EP3320902Feb 17, 2021Methods For Treating Diseases Using Isoindoline Compounds1
EP2797581May 6, 2020Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione3
EP2687213Jul 17, 2019Solid Forms Comprising (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione, Compositions Thereof, And Uses Thereof1
EP2223688May 29, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof5
EP2962690Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof15

Top competitors of Amgen Europe